Checkpoint Capital L.P. Acquires 165,000 Shares of Disc Medicine, Inc. $IRON

Checkpoint Capital L.P. grew its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 62.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 430,000 shares of the company’s stock after buying an additional 165,000 shares during the period. Disc Medicine accounts for about 9.5% of Checkpoint Capital L.P.’s holdings, making the stock its 4th biggest holding. Checkpoint Capital L.P. owned 1.14% of Disc Medicine worth $28,414,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IRON. TimesSquare Capital Management LLC purchased a new position in Disc Medicine in the 3rd quarter worth approximately $12,038,000. Y Intercept Hong Kong Ltd grew its position in shares of Disc Medicine by 361.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after purchasing an additional 33,905 shares in the last quarter. Atle Fund Management AB grew its position in shares of Disc Medicine by 85.3% in the third quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after purchasing an additional 21,038 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Disc Medicine by 11.1% in the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after purchasing an additional 84,278 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Disc Medicine in the third quarter valued at approximately $689,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Trading Up 0.5%

IRON opened at $60.04 on Friday. The stock has a market capitalization of $2.27 billion, a PE ratio of -10.02 and a beta of 0.87. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. The business’s 50 day moving average price is $71.11 and its 200 day moving average price is $75.73.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. As a group, equities research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IRON shares. Morgan Stanley set a $75.00 price objective on Disc Medicine in a research note on Tuesday, February 17th. Wells Fargo & Company raised their target price on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Stifel Nicolaus reduced their price target on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, January 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $104.80.

Insider Buying and Selling at Disc Medicine

In related news, insider Rahul Khara sold 6,500 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the sale, the insider directly owned 37,793 shares of the company’s stock, valued at approximately $2,973,931.17. This trade represents a 14.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 13,264 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at $14,210,383.04. The trade was a 5.54% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 206,985 shares of company stock worth $17,497,533. Insiders own 3.64% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.